FIDGETIN-LIKE 2 SIRNA-ENHANCED POLOXAMER-BASED HYDROGEL FOR WOUND HEALING
Methods and compositions for reducing a ratio of collagen III to collagen I in wounded skin, treating wounds and accelerating healing is provided with a surfactant polymer dressing comprising FL2 siRNA, collagen and a poloxamer.
1 . A cosmetic composition or pharmaceutical composition comprising (i) a siRNA directed to fidgetin-like 2 (FL2) associated with, or adsorbed to, a collagen particle in (ii) surfactant polymer dressing.
2 . The cosmetic composition or pharmaceutical composition of claim 1 , wherein the surfactant polymer dressing comprises a poloxamer.
3 . The cosmetic composition or pharmaceutical composition of claim 1 , wherein the collagen particles are microparticles, a microemulsion or micelles comprising collagen.
4 . The cosmetic composition or pharmaceutical composition of claim 1 wherein the collagen is collagen I.
5 . The cosmetic composition or pharmaceutical composition of claim 1 further comprising one or more antibiotic, antiseptic or anti-inflammatory compound, or any combination thereof.
6 . The cosmetic composition or pharmaceutical composition of claim 1 , further comprising a cosmetic or pharmaceutical ingredient, component or pharmaceutical carrier.
7 . The cosmetic composition or pharmaceutical composition of any one of claims 1 - 6 , wherein the siRNA is directed against a DNA or RNA encoding human fidgetin-like 2.
8 . The cosmetic composition or pharmaceutical composition of any one of claims 1 - 6 , wherein the siRNA has at least one 2′ sugar modification.
9 . The cosmetic composition or pharmaceutical composition of any one of claims 1 - 6 , wherein the fidgetin like-2 comprises the amino acid set forth in SEQ ID NO:2.
10 . The cosmetic composition or pharmaceutical composition of any one of claims 1 - 6 , wherein the siRNA comprises a sequence set forth in SEQ ID NOS:3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.
11 . A method of reducing a ratio of collagen III to collagen I in wounded skin during healing of a mammalian skin wound comprising a burn, the method comprising applying an amount of the cosmetic composition or pharmaceutical composition of claim 1 effective in reducing the ratio of collagen III to collagen I during healing of a burn wound.
12 . A method of treating a mammalian skin wound comprising applying an amount of the cosmetic composition or pharmaceutical composition of claim 1 effective to treat a mammalian skin wound.
13 . A method of accelerating healing of a mammalian skin wound comprising applying an amount of the cosmetic composition or pharmaceutical composition of claim 1 effective to accelerate healing of a mammalian skin wound.
14 . A method of decreasing inflammation and/or increasing in re-vascularization at a skin wound site, comprising applying an amount of the cosmetic composition or pharmaceutical composition of claim 1 effective to decrease inflammation and/or increase re-vascularization at a skin wound site.
15 . The method of any one of claims 12 - 14 , wherein the skin wound comprises an abrasion.
16 . The method of any one of claims 12 - 14 , wherein the skin wound comprises a cut.
17 . The method of any one of claims 12 - 14 , wherein the skin wound comprises an excision.
18 . The method of any one of claims 12 - 14 , wherein the skin wound comprises multiple lacerations.
19 . The method of any one of claims 12 - 14 , wherein the skin wound comprises a burn.
20 . A wound dressing structure comprising a portion having thereon a composition comprising (i) a siRNA directed to fidgetin-like 2 (FL2) encapsulated by collagen microparticles in (ii) surfactant polymer dressing.
21 . A wound dressing structure of claim 20 , wherein the surfactant polymer dressing comprises a poloxamer.
22 . A wound dressing structure of claim 20 , wherein the collagen is collagen I.
23 . A wound dressing structure of claim 20 , further comprising one or more antibiotic, antiseptic or anti-inflammatory compound, or any combination thereof.
24 . A wound dressing structure of claim 20 , wherein the siRNA is directed against a DNA or RNA encoding human fidgetin-like 2.
25 . A wound dressing structure of claim 20 , wherein the siRNA has at least one 2′ sugar modification.
26 . A wound dressing structure of claim 20 , wherein the fidgetin like-2 comprises the amino acid set forth in SEQ ID NO:2.
27 . A wound dressing structure of claim 20 , wherein the siRNA comprises a sequence set forth in SEQ ID NOS:3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.
28 . The wound dressing structure of claim 20 , further comprising one or more adhesive portions which permit adhesive attachment to mammalian skin.
29 . The wound dressing structure of claim 20 which structure comprises woven fabric, plastic, PVC, polyethylene, polyurethane, or latex.
30 . The wound dressing structure of claim 28 , comprising one or more adhesive portions, wherein the adhesive comprises an acrylate, methacrylate or epoxy diacrylate.
31 . The wound dressing structure of claim 20 , wherein the composition comprising (i) a siRNA directed to fidgetin-like 2 (FL2) encapsulated by collagen microparticles in (ii) surfactant polymer dressing is on, or adsorbed to, a skin-nonadhesive pad thereon.